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Previous studies have shown that injection of the mGlu5 receptor positive allosteric 
modulator (PAM) VU0360172 into either the thalamus or somatosensory cortex markedly 
reduces the frequency of spike-and-wave discharges (SWDs) in the WAG/Rij model of 
absence epilepsy. Here we have investigated the effects of VU0360172 on GABA transport 
in the thalamus and somatosensory cortex, as possible modes of action underlying the 
suppression of SWDs. Systemic VU0360172 injections increase GABA uptake in thalamic 
synaptosomes from epileptic WAG/Rij rats. Consistent with this observation, VU0360172 
could also enhance thalamic GAT-1 protein expression, depending on the dosing regimen. 
This increase in GAT-1 expression was also observed in the thalamus from non-epileptic rats 
(presymptomatic WAG/Rij and Wistar) and appeared to occur selectively in neurons. The 
tonic GABAA receptor current present in ventrobasal thalamocortical neurons was 
significantly reduced by VU0360172 consistent with changes in GAT-1 and GABA uptake. 
The in vivo effects of VU0360172 (reduction in tonic GABA current and increase in GAT-1 
expression) could be reproduced in vitro by treating thalamic slices with VU0360172 for at 
least 1 hour and appeared to be dependent on the activation of PLC. Thus, the effects of 
VU0360172 do not require an intact thalamocortical circuit. In the somatosensory cortex, 
VU0360172 reduced GABA uptake but did not cause significant changes in GAT-1 protein 
levels. These findings reveal a novel mechanism of regulation mediated by mGlu5 receptors, 
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Previous studies have shown that injection of the mGlu5 receptor positive allosteric modulator 
(PAM) VU0360172 into either the thalamus or somatosensory cortex markedly reduces the 
frequency of spike-and-wave discharges (SWDs) in the WAG/Rij model of absence epilepsy. Here 
we have investigated the effects of VU0360172 on GABA transport in the thalamus and 
somatosensory cortex, as possible modes of action underlying the suppression of SWDs. Systemic 
VU0360172 injections increase GABA uptake in thalamic synaptosomes from epileptic WAG/Rij 
rats. Consistent with this observation, VU0360172 could also enhance thalamic GAT-1 protein 
expression, depending on the dosing regimen. This increase in GAT-1 expression was also observed 
in the thalamus from non-epileptic rats (presymptomatic WAG/Rij and Wistar) and appeared to 
occur selectively in neurons. The tonic GABAA receptor current present in ventrobasal 
thalamocortical neurons was significantly reduced by VU0360172 consistent with changes in GAT-
1 and GABA uptake. The in vivo effects of VU0360172 (reduction in tonic GABA current and 
increase in GAT-1 expression) could be reproduced in vitro by treating thalamic slices with 
VU0360172 for at least 1 hour and appeared to be dependent on the activation of PLC. Thus, the 
effects of VU0360172 do not require an intact thalamocortical circuit. In the somatosensory cortex, 
VU0360172 reduced GABA uptake but did not cause significant changes in GAT-1 protein levels. 
These findings reveal a novel mechanism of regulation mediated by mGlu5 receptors, which could 










x VU0360172 is an mGlu5 receptor positive allosteric modulator  
x VU0360172 increases GABA uptake and reduces the tonic GABA current in the thalamus. 
x These effects selectively occur in the thalamus and not in the somatosensory cortex 
x These effects may contribute to the anti-absence effects of VU0360172 
 
 





Absence epilepsy is a form of generalized epilepsy characterized by sudden and transient episodes 
of behavioural arrest, which are associated with bilateral symmetrical spike-and-wave discharges 
(SWDs) in the electroencephalogram (EEG). SWDs are generated in a cortico-thalamo-cortical 
network, which includes thalamo-cortical neurons, pyramidal neurons of the somatosensory cortex, 
and GABAergic neurons of the reticular thalamic (RT) nucleus projecting to the ventrobasal (VB) 
thalamus. It has been proposed that pathological oscillations develop when enhanced activity at the 
GABAergic synapses between RT and VB neurons prevents deactivation of T-type voltage-
sensitive Ca2+ channels resulting in on-going generation of action potentials in thalamo-cortical 
(TC) neurons (Meeren et al., 2002; Blumenfeld, 2005). Drugs that are currently used for the 
treatment of absence epilepsy include the T-type Ca2+ channel blocker ethosuximide, and valproic 
acid, lamotrigine and clonazepam. All these drugs can be effective, but their use is limited by class-
related adverse effects. Moreover, over 20-30% of patients with absence epilepsy are resistant to 
pharmacological treatment or experience intolerable adverse effects (Mikati and Holme, 1997; 
Panayiotopoulos, 1999; Ollivier et al., 2009; Tenney and Glauser, 2013). These problems have 
encouraged the development of novel therapeutic strategies. One such strategy is to target 
metabotropic glutamate (mGlu) receptors, since most of the mGlu receptor subtypes are expressed 
in cortico-thalamo-cortical networks. Subsequently, several subtype-selective mGlu receptor 
ligands have been shown to be effective in reducing the incidence of seizures in animal models 
(Ngomba et al., 2011; 2018; Celli et al., 2019).  
Using the WAG/Rij rat model of absence epilepsy, we have previously identified mGlu5 receptors 
as a promising target. There is decreased mGlu5 receptor expression in the VB thalamus of both 
pre-symptomatic and symptomatic WAG/Rij rats, and mGlu5 receptor signalling is markedly 
reduced in the thalamus of symptomatic WAG/Rij rats. In contrast, mGlu5 receptor expression is 
enhanced in the somatosensory cortex of WAG/Rij rats, with no changes in receptor signalling 
(D’Amore et al., 2013). Systemic treatment with a selective positive allosteric modulator (PAM) of 
mGlu5 receptors (VU0360172) reduces the occurrence of SWDs without the development of 
tolerance (D’Amore et al., 2013; 2014). In an attempt to identify where within the cortico-thalamo-
cortical circuit mGlu5 receptors control the generation of SWDs, VU0360172 was infused into 
either the somatosensory cortex or the thalamus of WAG/Rij rats and it was found that both sites 
were involved in the anti-absence activity of the compound (D’Amore et al., 2015).  
Crunelli and associates have found that extrasynaptic GABAA receptor-dependent tonic inhibition is 
enhanced in thalamo-cortical neurons in different rodent models of absence epilepsy (Crunelli et al., 
Celli et al. 4 
 
 4 
2011), and that pharmacological activation of extrasynaptic GABAA receptors in the thalamus 
induces SWDs in non-epileptic animals (Cope et al., 2009). The enhanced tonic GABAergic 
inhibition resulted from reduced GABA uptake mediated by the transporter GAT-1 (Cope et al., 
2009). Mice with GAT-1 deletion showed spontaneous absence seizures that were sensitive to the 
anti-absence drugs, ethosuximide and valproate (Cope et al., 2009; Pirttimaki et al., 2013). To 
examine whether changes in GABAergic transmission were involved in the anti-absence activity of 
mGlu5 receptors, VU0360172 and the GAT-1 inhibitor, tiagabine, were locally infused in the VB 
thalamus or somatosensory cortex either alone or in combination. Intrathalamic infusion of 
tiagabine alone enhanced the occurrence of SWDs in WAG/Rij rats in a dose-dependent manner. 
Interestingly, VU0360172 lost its anti-absence activity when co-injected with subthreshold doses of 
tiagabine in the thalamus, and this combination even enhanced SWDs (D’Amore et al., 2015). This 
suggested that mGlu5 receptors require an intact and functional GABA transport system within the 
thalamus to suppress absence seizures. From this data it is a plausible hypothesis that mGlu5 
receptors act by boosting GABA uptake in the thalamus, thereby limiting the amount of synaptic 
GABA available for the activation of GABAA receptors in thalamo-cortical neurons. In contrast, 
inhibiting GABA uptake with tiagabine in the cortex suppressed SWDs similarly to VU0360172 
(D’Amore et al., 2015). This suggests that the suppressing action of VU0360172 probably has a 
different mechanism in the cortex compared to the thalamus.  
Here we have investigated the effects of enhancing the activation of mGlu5 receptors (with the 
PAM VU0360172) on GABA transport and transmission. The major focus of this study has been to 
investigate the effects of single injections of VU0360172 (its acute effects).  In some of the 
experiments we have also investigated the effects of multiple injections. We have found 
VU0360172 suppresses GABAA receptor-dependent tonic inhibition in the VB thalamus by up-
regulating GAT-1 expression and enhancing GABA uptake. These findings unravel novel mGlu5 
receptor-mediated regulation of inhibitory synaptic transmission that is a plausible mechanism for 
the effects of VU0360172 in reducing SWDs in models of absence epilepsy. 
 




VU0360172 (N-clyclobutyl-6-[2-3(fluorophenyl) ethynyl] pyridine-3-carboxamine), a selective 
mGlu5 receptor positive allosteric modulator (PAM), was purchased from Santa Cruz 
Biotechnology (Dallas, Texas, USA). VU0360172 was dissolved in 10% Tween 80 and injected 
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subcutaneously (s.c.). Fresh drug solution was prepared daily. VU0360172 was administered at the 
centrally active dose of 3 mg/kg (Rodriguez et al., 2010); control animals received equal volumes of 
10% Tween 80. U73122 was purchased from Sigma (Milan, Italy). For the incubation of acute 
thalamic slices, VU0360172 and U73122 were dissolved in dimethyl sulfoxide (DMSO) at the 
initial concentration of 10 mM. Aminooxyacetic acid (AOAA) was from SIGMA Aldrich (Milan, 
Italy). (RS)-3,5-dihydroxyphenylglycine (DHPG) was purchased from Tocris Bioscience (Bristol, 
United Kingdom); DHPG was dissolved in Krebs buffer at the initial concentration of 10 mM. 
GABAzine and kynurenic acid were obtained from Hello Bio (Bristol, UK).  
 
 
2.2 Ethical approval 
 
Procedures regarding animals were conducted in line with international and national regulations 
with the 3Rs concept. All animal care and experimental procedures at the University of Warwick 
were reviewed and approved by the institutional animal welfare and ethical review body (AWERB) 
and were in accordance with the Animals (Scientific Procedures) Act 1986.  
 
 
2.3 Animals and drug treatments 
We used three strains of rats: (i) male spontaneously epileptic WAG/Rij rats at 20-24 days and 5-6 
months of age. At 20-24 days of age, WAG/Rij rats do not show SWDs, and, are considered as pre-
symptomatic. In contrast, 5-6 months old WAG/Rij rats show about 16-20 SWDs per hour (van 
Luijtelaar and Coenen, 1988; Coenen and van Luijtelaar, 2003); (ii) age-matched Wistar rats, (as 
WAG/Rij rats originate from Wistar rats); and (iii) Sprague-Dawley rats. WAG/Rij and Wistar rats 
were used for studies of GAT-1 expression in the thalamus and somatosensory cortex; WAG/Rij 
rats were used for the study of [3H]-GABA uptake in superfused thalamic and cortical 
synaptosomes and for ex vivo studies of extrasynaptic GABAA-receptor mediated tonic inhibition in 
the thalamus; Sprague-Dawley rats were used for in vitro studies of tonic inhibition.  
For measurements of GAT-1 expression in the thalamus and somatosensory cortex, different groups 
of WAG/Rij (n=3-4 or n=4-5 per group) and age-matched Wistar rats (n = 4-5 per group) received 
either single or repeated multiple s.c. injections (5 injections with a 12-hour interval) with 
VU0360172 (3 mg/kg) or its vehicle. Animals were culled one hour after the last injection for 
measurements of GAT-1 mRNA and protein levels, and for immunohistochemical analysis. For ex 
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vivo measurements of GAT-1 in synaptosomal preparations, WAG/Rij rats received either single or 
multiple administrations of VU0360172 or its vehicle, as above.  
 
2.4 Assessment of GAT-1 expression 
Western blot analysis was carried out using the thalamus and somatosensory cortex dissected from 
WAG/Rij and age-matched control Wistar rats, at 20-24 days or 5-6 months of age (n = 3-5 rats per 
group). Tissue samples were homogenized at 4 °C in 50 mM Tris-HCl buffer, pH 7.4, containing 1 
mM EDTA, 1% Triton X-100, 1 mM PMSF, 1 mg/ml aprotinin, 1 mg/ml pepstatin, and 1 mg/ml 
leupeptin. Proteins were resuspended in SDS-bromophenol blue reducing buffer with 40 mM DTT. 
Western blot analysis were carried out with 10% SDS polyacrylamide gels, which were 
electroblotted onto immunoblot PVDF membranes; filters were blocked in TTBS buffer containing 
0.25% non-fatty milk. Specific rabbit polyclonal antibodies for GAT-1 (AB1570W, Chemicon, 
Millipore Corporation, Billerica, MA, 1:1000) or mouse monoclonal antibody for β-actin (1:50000, 
Sigma, St. Louis, MO) or GAPDH (1:1000, Abcam, Cambridge, UK) were used. Blots were then 
incubated with secondary antibodies (peroxidase-coupled anti-rabbit or anti-mouse, Amersham, 
Piscataway, NJ). Immunostaining was revealed by enhanced ECL (Amersham, Piscataway, NJ). 
 
2.5 Measurements of GABA uptake  
Purified cortical and thalamic synaptosomes were prepared essentially according to Dunkley et al. 
(1986), with minor modifications as follows. Briefly, the cortices and the thalami of control and 
treated rats were homogenized in 10 volumes of 0.32 M sucrose, buffered to pH 7.4 with TRIS 
(final concentration 0.01 M) using a glass Teflon tissue grinder (clearance 0.25 mm). The 
homogenate was centrifuged at 1000 x g for 5 min, to remove nuclei and debris; the supernatant 
was gently stratified on a discontinuous Percoll gradient (6%, 10% and 20% v/v in Tris-buffered 
sucrose) and centrifuged at 33,500 x g for 5 min. The layer between 10% and 20% Percoll 
(synaptosomal fraction) was collected and washed by centrifugation. The synaptosomal pellet was 
then resuspended in physiological medium (standard medium) having the following composition 
(mM): NaCl, 140; KCl, 3; MgSO4, 1.2; CaCl2, 1.2; NaH2PO4, 1.2; NaHCO3, 5; HEPES, 10 mM, 
glucose, 10; pH 7.2-7.4, AOAA 50 µM to avoid GABA metabolism. Synaptosomal protein contents 
were determined according to Bradford (1976). 
Aliquots of purified rat cortical (2.75 ± 0.17 mg protein / ml) and thalamic (1.25 ± 0.1 mg protein / 
ml) synaptosomes were first pre-incubated for 2 minutes in standard medium at 37 °C for 
equilibration. Then increasing concentrations (0.1 µM to 10 µM) of [3H]GABA solution were 
added to the suspension to allow the quantification of total tritium uptake. After 10 minutes of 
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incubation, the synaptosomal suspension was diluted by adding 3 ml of cold standard medium and 
immediately filtered under moderate vacuum using Whatman GF/B glass filters (GE Healthcare 
Life Sciences, Buckinghamshire, UK). Filters were rinsed with medium (3 ml for three times) at 
room temperature, collected and counted for radioactivity. Blanks were determined by incubating 
synaptosomes with the GABA solution at 2-4 C°. The specific activity of [3H]GABA was 30 
Ci/mmol (PerkinElmer Boston, MA, USA). To achieve the final concentrations (from 0.1 µM to 10 
µM) of the uptake substrate, 0.285µM [3H]GABA was added to a solution containing 100 µM 
unlabelled GABA (SIGMA, Milano, Italy) and the GABA solution diluted to reach the expected 
GABA concentrations to be tested. The amount of [3H]GABA taken up by the synaptosomes was 
calculated after subtraction of the respective blank. The amount of [3H]GABA in the filter was 
expressed as nCi per mg of protein and it was determined by considering the dilution with the 
unlabelled GABA. Data handling, statistics and graph construction was carried out using SigmaPlot 
10 (Systat software). The results were expressed as the amount of [3H]GABA taken up in each 
experimental condition.  
 
2.6 Immunohistochemical analysis of GAT-1 expression 
Rats were deeply anesthetized and cardiac perfused with ice-cold 4% paraformaldehyde, brains 
were carefully removed and equilibrated with 30% sucrose overnight. Brain tissue was sectioned 
using a Leica cryostat (CM3050). For immunofluorescence analysis, 30 Pm serial sections were 
incubated with blocking solution (5% normal serum in 0.3% Triton X-100 in PBS) and then with 
the following antibodies overnight at 4 °C: rabbit anti-GAT1 primary antibody (1:300, Millipore, 
Darmstadt, Germania) and mouse anti-GFAP primary antibody (1:250, Millipore, Darmstadt, 
Germania). Serial sections were then incubated with the respective secondary antibody conjugated 
to Alexa Fluor 488 (1:200, Molecular Probes, Eugene) and Cy3 (1:200, Jackson ImmunoResearch 
Labs, West Grove, PA). Finally, sections were mounted with anti-fading agent containing DAPI for 
nuclear staining (Vector Laboratories, Burlingame, CA) and examined with ZEISS 780 confocal 
laser scanning microscope (488 nm argon laser to excite Alexa 488 and 543 nm HeNe laser to 
excite Cy3). 
 
2.7 Measurements of GAT-1 mRNA levels  
Total RNA was extracted from the thalamus and somatosensory cortex using the trizol reagent 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. The RNA was further 
treated with DNAse (Qiagen, Hilden, Germany), and single strand cDNA was synthesized from 1.5 
μg of total RNA using Superscript III (Invitrogen) and random hexamers. Real-time PCR was 
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performed on 15 ng of cDNA by using the following primers and Power SYBR Green Master Mix 
(Biorad, Hercules, CA) on an Applied Biosystems Step-One instrument. Slc6a1 – GAT-1 forward: 
GCAATCGCCGTGAACTCTTC; reverse: AGGAAATGGAGACACACTCAAAGA and E-actin 
forward: GTTGACATCCGTAAAGACC; reverse: TGGAAGGTGGACAGTGAG. Thermal cycler 
conditions: 10 min at 95°C, 40 cycles of denaturation (15 sec at 95°C), and combined 
annealing/extension (1 min at 58-60°C). mRNA copy number was calculated from serially diluted 
standard curves simultaneously amplified with the samples and normalized with respect to E-actin 
mRNA copy number. Each sample was analyzed in duplicate together with two negative controls. 
 
2.8 In vitro stimulation of thalamic mGlu5 receptors  
Thalamic slices (350 x 350 Pm) were prepared from male adult Wistar rats with a McIlwain tissue 
chopper. Animals were killed by decapitation, and the thalamus was dissected out and transferred in 
ice-cold Krebs-Henseleit buffer (NaCl 118 mM, KCl 4.7 mM, MgSO4 1.18 mM, KH2PO4 1.18 
mM, NaHCO3 24.8 mM, CaCl2 1.2 mM, D-glucose 10 mM) that had been pre-gassed with 95% O2 
and 5% CO2 to pH 7.4. Gravity packed slices (30 Pl) were incubated for 45 min in 350 Pl of buffer 
for metabolic recovery. Slices were then incubated with U73122 (10 PM) or its vehicle for 15 min 
and followed by VU0360172, 1 mM and DHPG, 200 mM. One hour later, the incubation was 
stopped by addition of 50 Pl of a lysis buffer (Tris-HCl, 100 mM; pH 7.5; containing 5 M NaCl, 0.5 
M EDTA, 1% IGEPAL, 10% SDS and a cocktail of protease inhibitors). Tissue samples were 
homogenized by sonication and used for Western blot analysis of GAT-1. 
 
2.9 Electrophysiological recording of tonic GABAA receptor current  
In the first set of experiments tonic GABAA receptor current was measured ex vivo in 
thalamocortical slices obtained from P20-24 WAG/Rij rats injected (s.c) at least one hour before 
with either vehicle or VU0360172 (3 mg/kg). In a second set of experiments the tonic GABAA 
receptor current was measured in thalamocortical slices obtained from P18-20 Sprague Dawley rats 
incubated in vitro (for at least 1 hour) with VU0360172 or vehicle. Transverse thalamocortical 
slices (300-350 Pm) were prepared using a Microm HM 650V microslicer in cold (2-4°C) high 
Mg2+, low Ca2+ aCSF, composed of (mM): 127 NaCl, 1.9 KCl, 8 MgCl2, 0.5 CaCl2, 1.2 KH2PO4, 26 
NaHCO3, 10 D-glucose (pH 7.4 when bubbled with 95% O2 and 5% CO2, 300 mOSM). Slices 
were stored at 34°C for 1-6 hours in aCSF (1 mM MgCl2, 2 mM CaCl2) before use. To measure the 
in vitro effects of VU0360172 incubation, thalamic slices were cut in half down the mid-line, and 
one half was kept in control conditions (vehicle, DMSO) and the other half was pre-incubated for at 
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least one hour in VU0360172 (5 PM). DMSO was added to the control aCSF (0.0125 %) so it was 
the same concentration as for slices incubated in VU0360172. 
For patch clamp recording, an individual slice was transferred to the recording chamber and 
perfused at 3 ml min-1 with aCSF at 32 ± 0.5°C containing 2.5 mM kynurenic acid (to block 
glutamatergic transmission). Slices were visualized using IR-DIC optics with an Olympus BX151W 
microscope (Scientifica) and a CCD camera (Hitachi). Whole-cell patch clamp recordings were 
made from thalamocortical neurons using patch pipettes (5–10 MΩ) manufactured from thick 
walled glass (Harvard Apparatus, Edenbridge UK) either containing (mM): 135 mM CsCl, 10 
HEPES, 10 EGTA, 2 Mg-ATP pH 7.2 with TEA-OH) for voltage clamp recordings or potassium 
gluconate 135, NaCl 7, HEPES 10, EGTA 0.5, phosphocreatine 10, MgATP 2, NaGTP 0.3 (293 
mOSM, pH 7.2) for current clamp recordings. Recordings were obtained using an Axon Multiclamp 
700B amplifier (Molecular Devices, USA) and digitised at 10 KHz. Data acquisition and analysis 
was performed using Pclamp 10 (Molecular Devices). For voltage clamp recordings, neurons were 
held at -70 mV and the tonic current was measured as the difference between the holding current in 
control and following the application of GABAzine (100 PM). To accurately measure the shift in 
holding current, all point histograms were constructed from 20 s of data in control and after 
application of GABAzine (using Origin, Microcal). Each histogram was fitted with a single 
Gaussian (non-linear least-squares Levenberg-Marquadt algorithm, Origin Microcal) so the mean 
current at the peak could be measured (Wall and Usowicz, 1997).  
 
2.10 Statistical analysis  
All data are presented as the means ± SEM. Statistical analysis was performed using Student’s t-
test, Kruskal-Wallis test and one-way ANOVA + Bonferroni’s post hoc test. The tests used are 
indicated in the figure legends. In all studies, n indicates the number of samples per group, and 





3.1 Selective pharmacological enhancement of mGlu5 receptor function up-regulates GABA uptake 
and GAT-1 protein levels in the thalamus of symptomatic and presymptomatic WAG/Rij rats 
To investigate whether VU0360172 modulates thalamic GABA signalling, we first investigated 
whether VU0360172 could alter thalamic GABA uptake. Experiments were performed ex vivo with 
synaptosomes prepared from the thalamus of symptomatic WAG/Rij rats treated systemically with 
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either a single injection or five multiple injections (12 hour interval between injections) of 
VU0360172 or vehicle. Thalamic synaptosomes were prepared 1 hour after the last drug injection 
and incubated with increasing concentrations of [H3]GABA. The uptake of GABA was significantly 
enhanced after either single or multiple injections of VU0360172 (Fig. 1A, B). The increase became 
statistically significant with the two highest concentrations of [H3]GABA (Fig. 1A, B).  
To examine whether changes in the expression of the GABA transporter GAT-1 underlies the 
observed increase in GABA uptake, GAT-1 protein expression was measured in the thalamus from 
symptomatic WAG/Rij rats treated with either VU0360172 or vehicle. Western blot analysis 
showed significant increases in thalamic GAT-1 protein expression one hour after a single injection 
of VU0360172 (Fig. 1C). However, GAT-1 expression returned back to control levels after multiple 
injections of VU0360172, although GABA uptake remained significantly enhanced (Fig. 1B). We 
then investigated if equivalent changes in GAT-1 could also occur in presymptomatic WAG/Rij rats 
(P20-24, Fig. 1D) and found similar to symptomatic WAG/Rij rats, a single injection of 
VU0360172 significantly enhanced GAT-1 expression, whereas after multiple injections GAT-1 
expression was not significantly different from vehicle (Fig. 1D).   
 
3.2 Selective pharmacological enhancement of mGlu5 receptor activation can increase GAT-1 
expression in the thalamus of non-epileptic rats  
Since a single injection of VU0360172 enhanced GAT-1 expression in the thalamus of 
presymptomatic WAG/Rij rats, we next investigated whether similar effects could be observed in 
the thalamus from age-matched non-epileptic control rats (Wistar, since WAG/Rij rats were 
originally derived from Wistar). A single injection of VU0360172 significantly increased thalamic 
GAT-1 protein levels in 20-24 day old (age matched to presymptomatic WAG/Rij rats) and in 5-6 
month old Wistar rats (aged matched to symptomatic WAG/Rij rats, Fig. 2A, B). GAT-1 expression 
returned to control levels after multiple drug injections in the 20-24 day old Wistar rats but 
remained significantly elevated in 5-6 month old Wistar rats (Fig. 2A, B). The increase in GAT-1 
expression produced by VU0360172 in presymptomatic WAG/Rij rats and in non-epileptic control 
rats (Wistar), suggests that there is not a requirement for abnormal network activity in the thalamus 
for VU0360172 to have its effects on GAT-1 expression.  
 
3.3 The changes in GAT-1 expression are not associated with changes in mRNA  
We next investigated whether the increase in GAT-1 expression was associated with an increase in 
GAT-1 mRNA. Surprisingly, the increase in GAT-1 protein expression induced by a single 
injection of VU0360172 in Wistar rats was not associated with significant changes in GAT-1 gene 
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transcription (two-sample t(4) = -0.101, p = 0.92). This suggests that there may either be changes in 
the rate of translation of pre-existing GAT-1 mRNA or that there are post-translational changes 
such as an increase in GAT-1 protein half-life.  
 
 
3.4 GAT-1 expression is increased in neurons not glia  
To investigate the cellular distribution of the increased GAT-1 expression, immunohistochemistry 
and confocal imaging was performed using thalamic slices labelled with GAT-1 and GFAP (to label 
glia) antibodies (Fig. 3). The analysis was performed in 20-24 day old WAG/RIJ and Wistar rats 
receiving either a single injection of VU0360172 or vehicle. In control conditions (vehicle) GAT-1 
appeared to be expressed in neurons (as it did not co-localise with GFAP) and showed a perinuclear 
localization (Fig. 3). Following a single injection of VU0360172 there was increased GAT-1 
labelling in both Wistar and WAG/Rij rats consistent with the western blot data (see Figs 1 and 2). 




3.5 Enhancement of mGlu5 receptor activation decreases tonic GABAA receptor current in VB 
thalamocortical neurons 
Thalamocortical (TC) neurons in the VB thalamus receive two forms of GABAergic transmission: 
(i) phasic, mediated by synaptic GABAA receptors (containing of D1-3, E, and J subunits); and, (ii) 
tonic, mediated by high affinity extra synaptic GABAA receptors containing the G subunit (Belelli et 
al., 2005; Cope et al., 2005; Jia et al.,2005). It would be reasonable to predict that the increase in 
GABA uptake and GAT-1 expression produced by VU0360172 administration would reduce the 
tonic GABAA receptor current in TC neurons. To assess this, we made whole cell patch clamp 
recordings from TC neurons in thalamic slices prepared from 20-24 days old WAG/Rij rats which 
had received either a single injection of VU0360172 or vehicle. TC neurons in the VB thalamus 
were identified by their position in the slice and their characteristic current-voltage relationship 
(Fig. 4A). The upward shift in holding current produced by the GABAA receptor antagonist 
GABAzine (100 PM) was used to quantify the tonic GABAA receptor current (Fig. 4B, C). There 
was a significant (p = 0.005776) reduction in the amplitude of the tonic current in rats treated with 
VU0360172 compared to vehicle treated littermates  
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3.6 The effects of VU0360172 on GAT-1 expression can be reproduced in vitro and occurs by PLC 
activation 
Since the effects of VU0360172 occurred in non-epileptic control rats (Wistar), they do not appear 
to require abnormal activity to be produced. We therefore wondered if they could be reproduced in 
vitro with either a quiescent or incomplete thalamocortical circuit. Initially we investigated changes 
in GAT-1 expression. Experiments were performed using acute thalamic slices that had been 
incubated in either VU0360172 or the mGlu1/5 orthosteric agonist, DHPG or with vehicle. 
Incubation of thalamic slices with VU0360172 (1 PM) or DHPG (200 PM) significantly increased 
GAT-1 protein expression (Fig. 5A), consistent with data obtained after a single systemic injection 
of VU0360172.  
mGlu5 receptors are coupled to Gq/11 proteins, and their activation stimulates phospholipase-CE 
(PLCE), which converts phosphatidylinositol-l,4,5-bisphosphate into inositol-1,4,5-trisphosphate 
and diacylglycerol (Nicoletti et al., 2011). To examine whether this transduction mechanism was 
involved in the modulation of GAT-1 expression we used the PLC inhibitor, U73122 (Burgdorf et 
al., 2010; Shen et al., 2013). The effects of DHPG and VU0360172 on GAT-1 expression were 
abolished by co-incubating slices with U73122 (10 PM, applied 20 min prior to VU0360172 or 
DHPG incubation, Fig. 5B).  
We then investigated whether the effects of mGlu5 receptor activation on tonic GABAA receptor 
current occur in vitro. Thalamic slices from four rats were cut in half, with one half incubated for at 
least one hour with VU0360172 (5 PM) and the other half incubated with vehicle (DMSO). Whole 
cell patch clamp recordings where then made from VB TC neurons in interleaved VU0360172 (5 
PM) and vehicle treated slices (Fig. 6A, B). There was a significantly smaller tonic GABAA 
receptor current in slices incubated in VU0360172 compared to slices incubated in vehicle. This 
data suggests that the effects of VU0360172 can occur when the thalamocortical circuit is not intact 
and must therefore be localised to the thalamus. 
 
 
3.7 Effect of VU0360172 on GABA uptake and GAT-1 expression in the somatosensory cortex 
It was previously shown that injecting VU0360172 into the somatosensory cortex reduced the 
frequency of SWDs in WAG/Rij rats (D'Amore et al., 2015). Therefore, we investigated the effects 
of VU0360172 on GABA signalling in the somatosensory cortex. In contrast to what was observed 
with thalamic synaptosomes, a significant reduction in [H3]GABA uptake was observed in cortical 
synaptosomes prepared from 5-6 month old symptomatic WAG/Rij rats that had received a single 
injection of VU0360172 (Fig. 7A). [H3]GABA uptake returned back to control levels after multiple 
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injections of VU0360172 (Fig. 7B). No changes in GAT-1 protein expression were found in the 
somatosensory cortex of either symptomatic or pre-symptomatic WAG/Rij rats (Fig. 7C, D) or in 5-
6 month old Wistar rats receiving either single or multiple injections of VU0360172 (not 
illustrated). There was also no significant change in GAT-1 mRNA expression in response to 
VU0360172 (not illustrated, GAT-1 mRNA levels were 14300 + 2090 vs 13400 + 1470 copy 
number/106 E-actin copy number in the cortex of Wistar rats receiving a single injection of 





Our data outlines a novel mechanism by which mGlu5 receptors modulate GABA transmission: 
enhancement of mGlu5 receptor activation increases GABA uptake in the thalamus of epileptic 
WAG/Rij rats. This mechanism holds promise for the treatment of absence epilepsy because 
defective GABA uptake has been linked to the pathophysiology of SWDs in a variety of preclinical 
models of absence epilepsy (Cope et. al, 2009). In addition, drugs that enhance 
synaptic/extrasynaptic GABA levels, such as tiagabine and vigabatrine, exacerbate absence seizures 
(Coenen et al., 1995; Panayiotopoulos, 1999; Errington et al., 2011), and increases in thalamic 
GABA levels have been linked to the expression of cortical spike and wave complexes in a patient 
with atypical childhood absence epilepsy (Leal et al., 2016). The enhanced GABA uptake would be 
expected to limit the activation of extrasynaptic GABAA receptors, which mediate tonic inhibition. 
Accordingly, activation of mGlu5 receptors with VU0360172 reduced tonic GABAergic inhibition. 
These findings further strengthen the value of mGlu5 receptors as candidate drug targets for the 
treatment of absence epilepsy because tonic GABAA current is increased in various experimental 
animal models of absence epilepsy prior to the onset of, and during absence seizures (Cope et al., 
2009; Errington et al., 2011; 2014).  
 
 
4.1 How does VU0360172 enhance GAT-1 expression? 
A single systemic injection of VU0360172 produced a rapid increase in GAT-1 protein levels in the 
thalamus, but not in the somatosensory cortex. An increase in GAT-1 levels was also found in vitro 
with thalamic slices incubated with either VU0360172 or the orthosteric mGlu1/5 receptor agonist, 
DHPG. This suggests that the effects of mGlu5 activation on GAT-1 expression are local to the 
thalamus, do not require an intact thalamo-cortico-thalamic circuit, can occur when the circuit is 
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relatively quiescent, and can occur within a short timeframe (1 hour). These changes appear too 
rapid to be explained by a genomic effect of mGlu5 receptor activation, and indeed we found that 
the transcript of GAT-1 receptor was unchanged 1 hour after systemic treatment with VU0360172. 
It is therefore possible that mGlu5 receptor activation increases the amount of GAT-1 available for 
GABA uptake by for example reducing GAT-1 degradation and/or enhancing translation of 
preformed mRNA. Stimulation of PI hydrolysis, resulting in an increase in intracellular free Ca2+ 
concentrations and activation of protein kinase C may drive these changes because, at least in 
thalamic slices, pharmacological blockade of PLC (with U73122) prevented the increase in GAT-1 
protein levels induced by either VU0360172 or DHPG. However, since U73122 may not be entirely 
selective for PLC (for example see MacMillan and McCarron 2010) additional studies with other 
PLC inhibitors are required to prove this conclusively.  
 
 
4.2 Increased GAT-1 expression occurs in neurons not glia  
A reduction in astrocytic GAT-1 activity has been associated with the epileptic phenotype of the 
absence model GAERS (Pirttimaki et al., 2013). However, our immunohistochemistry experiments 
showed that the increase in GAT-1 levels was restricted to thalamic neurons and did not occur in 
glia. mGlu5 receptors are expressed in both neurons and astrocytes; however, their expression is 
low in resting astrocytes and only becomes substantial when astrocytes become reactive, both in 
vitro (Miller et al., 1995) and in vivo (Aronica et al., 2000; Ulas et al., 2000; Drouin-Ouellet et al., 
2011). The presence of reactive astrocytes in the thalamus of genetic animal models of absence 
epilepsy is controversial. While Dutuit et al. (2000) found increased GFAP expression in the 
thalamus of pre-symptomatic and symptomatic GAERS, no reactive astrocytes were found in 
extracortical regions of GAERS in a more recent study (Akin et al., 2011). In addition, we found 
that activation of mGlu5 receptors could also up-regulate GAT-1 activity levels in the thalamus of 
non-epileptic rats, in which reactive astrocytes are expected to be absent. Thus, while defective 
activity of glial GAT-1 might be linked to the pathophysiology of absence seizures (Pirttimaki et 
al., 2013), an up-regulation of neuronal GAT-1 in the thalamus may contribute to the acute anti-
absence effect of drugs that activate mGlu5 receptors. Interestingly GAT-1 protein levels returned 
back to normal after multiple injections of VU0360172 whereas the enhanced GABA uptake found 
ex vivo in thalamic synaptosomal preparation persisted after multiple administrations of 
VU0360172. This suggests that an increased GAT-1 activity maintains the response to VU0360172 
over time in spite of the normalization of the overall GAT-1 protein levels, thus avoiding the 
development of tolerance. This hypothesis is consistent with the evidence that the anti-absence 
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activity of systemically administered VU0360172 in WAG/Rij rats persisted for at least 10 days 
(D’Amore et al., 2014).  
 
4.3 Comparison with blocking GABA uptake in vivo  
Our previous work has shown that GAT-1 blockade with tiagabine has opposite effects on absence 
seizures in WAG/Rij rats if the drug is locally injected in either the thalamus or into the 
somatosensory cortex. Intrathalamic infusion of tiagabine induced the expected increase in SWD 
incidence, whereas, surprisingly, intracortical infusion reduced absence seizure occurrence 
(D’Amore et al., 2015). Interestingly, the modulation of GABA uptake by mGlu5 receptors also 
differed between the thalamus and the somatosensory cortex. Whilst, systemic treatment with 
VU0360172 enhanced GABA uptake in thalamic synaptosomes, a single injection of the drug 
reduced GABA uptake in cortical synaptosomes, thus mimicking the action of intracortical 
tiagabine. Tolerance developed to the effect of VU0340172 in the somatosensory cortex, and no 
changes in cortical GABA uptake were seen after multiple injections of VU0360172. In addition, 
there were no changes in cortical GAT-1 expression in response to either single or multiple 
administrations of VU0360172. This dismisses the possibility that mGlu5 receptors are physically 
and uniformly linked to the molecular machinery of GABA uptake across the CNS, and rather 
suggests that mGlu5 receptor signalling modulates GABA uptake at multiple levels in a region- and 
context-dependent manner. Our findings nicely explain why, in WAG/Rij rats, intrathalamic 
VU0360172 loses its anti-absence activity when co-injected with sub-threshold doses of tiagabine, 
whereas both VU0360172 and tiagabine display anti-absence activities when co-injected in the 
cortex (D’Amore et al., 2015).  
Even though the origin of the SWDs appears to be localised in the somatosensory cortex of 
WAG/Rij rats (Meeren et al., 2002), the enhancement of GABA uptake in the VB thalamus might 
represent a key mechanism by which mGlu5 receptor activation causes a rapid and sustained 
protective effect against absence seizures. That said, reduced GABA uptake in the somatosensory 
cortex might equally contribute to the acute (but not chronic) anti-absence effect of mGlu5 receptor 
activation, in the WAG/Rij rat model. Accordingly, reductions of SWD incidence were similar in 
terms of extent and temporal profile following VU0360172 injection in the VB thalamus and 
somatosensory cortex of WAG/Rij rats (D’Amore et al., 2015).   
 
4.4 Conclusion  
By definition, mGlu5 PAMs amplify receptor function in an activity-dependent manner, requiring 
glutamate binding to the receptor for their pharmacological activity. We therefore expect that these 
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drugs are particularly effective when the receptors are highly activated by endogenous glutamate (as 
likely occurs during pathological oscillations within the cortico-thalamo-cortical network), and this 
might optimize the ratio between efficacy and tolerability in the treatment of absence epilepsy. 
mGlu5 receptor PAMs display robust antipsychotic and pro-cognitive activity, and are under 
development for the treatment of schizophrenia (Bruno et al., 2017; Maksymetz et al., 2017; 
Stansley and Conn, 2018). Some of the PAMs may cause convulsive seizures and excitotoxic 
neuronal death when systemically injected at high doses (Rook et al., 2013; Parmentier-Batteur et 
al., 2014; Conde-Ceide et al., 2016). These harmful effects may reflect the recruitment of NMDA 
receptors through a mechanism of mGlu5/NMDA receptor crosstalk (Awad et al., 2000; Mannaioni 
et al., 2001; Pisani et al., 2001). Stimulus-biased mGlu5 PAMs that do not recruit NMDA receptors, 
such as compound VU0409551 (Rook et al., 2015), may overcome this limitation. The evaluation 
of VU0409551 and other stimulus-biased mGlu5 PAMs will be an important step in translational 
research for the use of mGlu5 PAMs in the treatment of absence epilepsy. 
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Figure 1. Pharmacological enhancement of mGlu5 receptor activation increases thalamic 
GABA uptake and GAT-1 expression.  
A, The uptake of [3H]-GABA by synaptosomes prepared from the thalamus of symptomatic 
WAG/Rij rats treated with a single injection of VU0360172 (3 mg/kg, s.c.) or vehicle. B, The same 
as (A) but for 5 multiple injections (interval of 12 hours). Values are means + S.E.M. of 
radioactivity (in nCi) taken up per mg of synaptosomal proteins (the points are data are from 
individual experiments). *Statistically significant vs. the respective vehicle (A, 3 PM GABA two-
sample t(6) = -3.82, p = 0.009, 10 PM GABA two-sample t(6) = -3.91, p = 0.008, B, 3 PM GABA 
two-sample t(4) = -2.8, p = 0.048; 10 PM GABA two-sample t(6) = -4.38, p = 0.005).  
C, Representative immunoblot and analysis of GAT-1 expression in the thalamus of symptomatic 
5-6 months WAG/Rij rats. Values are means + S.E.M. with 3-4 animals in each group. Data points 
show data from individual experiments. *Statistically significant difference between treatment 
groups by one-way ANOVA [( F = 8.020, p = 0.005, df = 3) and pairwise multiple comparison 
procedures with Bonferroni correction (alpha = 0.050) between vehicle and single injection 
VU030172, with P=0.045)] D, Immunoblot analysis of GAT-1 expression in pre-symptomatic 20-
24 days old WAG/Rij rats. Values are means + S.E.M. with 4-5 animals in each group. Data points 
are from individual experiments.  Single injection: *Statistically significant Vs respective vehicle (t 
= -4.089, df= 7, and 95 percent two-tailed confidence interval for difference of means: -0.549 to -
0.147; Two-tailed P = 0.00464); Multiple injection: no statistically detected difference between 
groups (t = -1.819, df =7, and 95 percent two-tailed confidence interval for difference of means: -
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Figure 2. Pharmacological enhancement of mGlu5 receptor activation can increases thalamic 
GAT-1 expression in non-epileptic rats 
A, Immunoblot analysis of GAT-1 expression in Wistar rats age-matched to presymptomatic 
WAG/Rij rats (P20-24) and B, Wistar rats age-matched to symptomatic WAG/Rij rats (5-6 month 
old). Values are means + S.E.M. with 4-5 animals in each group. Data points show data from single 
experiments. A, single injection: *Statistically significant Vs respective vehicle (t = -7.119, df = 7 ; 
95 percent two-tailed confidence interval for difference of means: -1.390 to -0.697; Two-tailed p = 
0.0001); multiple injection: no statistically detected difference between groups (t = -1.314, df =7 ; 
95 percent two-tailed confidence interval for difference of means: -0.336 to 0.0958; Two-tailed p = 
0,230); B, *Statistically significant Vs respective vehicle [single injection (t = -4.169, df = 7; 95 
percent two-tailed confidence interval for difference of means: -0.938 to -0.259; Two-tailed p = 
0.00420; multiple injection (t = -5.921 df = 7 ; 95 percent two-tailed confidence interval for 
difference of means: -1.202 to -0.516; Two-tailed p = 0.000587)]. 
 
 
Figure 3. The increase in GAT-1 expression occurs in thalamic neurons. 
Photomicrographs illustrating GAT-1 expression in the VB thalamus of WAG/Rij rats (P20-24) that 
had received either a single injection of VU0360172 or vehicle. GAT-1 is labelled in green with the 
astrocyte marker glial fibrillary acidic protein (GFAP) in red. The increase in GAT-1 expression in 
response to VU0360172 does not appear to co-localise with GFAP and thus presumably occurs in 
neurons.  
 
Figure 4. Systemic treatment with the VU0360172, reduces the tonic GABAA receptor current 
in thalamocortical neurons 
A, Example of voltage responses to current injections characteristic of a thalamocortical neuron (for 
example observe initial burst and rebound firing following hyperpolarisation steps). B, Example 
current traces (neurons held at -70 mV) recorded from thalamocortical neurons in slices from 20-24 
day old WAG/Rij rats which had received a single injection of VU0360172 or vehicle. Application 
of the GABAA receptor antagonist GABAzine (100 PM) produced a much larger upward shift in 
holding current in the neuron from the vehicle treated WAG/Rij rat compared to the VU0360172 
treated rat. C, All point histograms constructed from the data in (B) and fitted with single Gaussian 
distributions (mean current in vehicle treated rats: control -76.4 ± 5.1 pA, GABAzine -48.4 ± 4.06 
pA, shift in current ~ 28 pA; in VU0360172 treated: control -64.4 ± 6.3, GABAzine -60.8 ± 4.88 
pA, shift in current ~ 5 pA). D, Summary plot of data from 4 vehicles and 4 VU0360172 treated 
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littermates. Each point is the mean of the GABAzine induced shift in holding current from 3-4 
slices from each rat. The lines link the data from littermates which were recorded interleaved on the 
same day in slices from vehicle and VU0360172 treated animals. *There is a significant (paired t(3) 
= -7.08, p = 0.00579 reduction in the shift in holding current (vehicle: -24.1 ± 4.3 pA; 
VU03601725.7 ± 1.8 pA, n = 4 rats, 12 slices). 
 
 
Figure 5. Activation of mGlu5 receptors enhances GAT-1 protein expression in vitro via the 
stimulation of phospholipase C (PLC). 
A, Representative immunoblot and analysis of GAT-1 protein expression in acute thalamic slices 
incubated with either vehicle, DHPG (200 PM) or VU0360172 (1 PM). Both DHPG and 
VU0360172 significantly enhanced GAT-1 expression (*Statistically significant: P= 0.005, degrees 
of freedom = 2, test statistic = 10.460 and Total N = 24, by independent samples Kruskal-Wallis 
test). The significance values have been adjusted by the Bonferroni post-hoc test; B, Representative 
immunoblot and analysis of GAT-1 protein expression incubated with either vehicle, DHPG (200 
PM) or VU0360172 (1 PM) in the presence of the PLC inhibitor, U73122 (10 PM). There was no 
significant effect of both DHPG and VU0360172, against vehicle in the presence of U73122 ( P= 
0.786, degrees of freedom = 2, test statistic = 0.482 and Total N = 10, by independent samples 
Kruskal-Wallis test). The test statistic is adjusted for ties. Values are means + S.E.M. Data points 
show data from single experiments. 
 
Figure 6. The effect of VU0360172 on the tonic GABAA receptor current in thalamocortical 
neurons can be repeated in vitro 
A, Example current traces (neurons held at -70 mV) recorded from thalamocortical neurons in acute 
thalamic slices incubated with either vehicle (DMSO) or VU0360172 (5 PM) for at least 1 hour. 
The GABAA receptor antagonist GABAzine (100 PM) reduced the tonic GABA current (upward 
shift in holding current). GABAzine had less effect on the holding current in the neuron from the 
slice incubated with VU0360172 compared to the interleaved slice incubated in vehicle B, Graph 
summarizing data from 7-9 slices. The shift in holding current produced by GABAzine is 
significantly (two-sample t (14) = 3.23, p = 0.0071) smaller in slices pre- incubated in VU0360172 
(mean shift in holding current 17.3 ± 3.8 pA) compared to those incubated in vehicle (mean shift in 
holding current 57.0 ± 4 pA). The points are the GABAzine-induced shift in holding current 
measured from individual slices.  
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Figure 7. Effect of systemic treatment with VU0360172 on GABA uptake and GAT-1 
expression in the somatosensory cortex 
A, The uptake of [3H]-GABA by synaptosomes prepared from the neocortex of symptomatic 
WAG/Rij rats treated with a single injection of VU0360172 or vehicle. B, The same as (A) but for 5 
multiple injections (interval of 12 hours) of either VU0360172 or vehicle. Values are means + 
S.E.M. of radioactivity (in nCi) taken up per mg of synaptosomal proteins. The data points are data 
from individual experiments. *Statistically significant vs. the respective vehicle (A, 3 PM GABA 
two-sample t(4) = 2.74, p = 0.049, 10 PM GABA two-sample t(5) = -3.12, p = 0.025).   
C, Representative immunoblot and analysis of GAT-1 expression in the somatosensory cortex of 
symptomatic 5-6 months WAG/Rij rats (n = 3-4), and in (D) pre-symptomatic 20-24 days old 
WAG/Rij rats (n = 4-5), receiving either single or multiple injections of VU0360172 or vehicle. 
Values are means + S.E.M with (C) 3-4 or (D) 4-5 animals in each group). There were no 
significant differences in GAT-1 expression in the somatosensory cortex between animals pre-
treated with VU0360172 and vehicle [C, by one-way ANOVA: F = 0.937, p = 0.458, df = 3). D, 
single injection (t = -1.124, df = 7 ; 95 percent two-tailed confidence interval for difference of 
means: -0.887 to 0.315; Two-tailed P= 0.298); multiple injection( t = 0.284, df = 7 ; 95 percent two-
tailed confidence interval for difference of means: -0.553 to 0.704; Two-tailed P = 0.785)]. 
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